RxDoctor Payments Data

Frank Balis

Pediatric Hematology-Oncology · Philadelphia, PANPI 1780803924

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $625 of the $625 with a category attached, or 100.0%. Every reported general payment came from a single manufacturer, Day One Biopharmaceuticals.

$625in general payments, 2019–2025

Across 1 payment — averaging $625.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Day One Biopharmaceuticals$625
$4,660,537in research payments, 2019–2025

Across 113 payments — averaging $41,244 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eisai Inc.$2.4M
  • Jazz Pharmaceuticals Inc.$1.7M
  • United Therapeutics Corporation$197K
  • Eli Lilly$128K
  • Novartis$61K
  • Genentech, Inc.$58K
  • plus $54K from 7 others

What the payments were for

  • Consulting fees$625100%

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Day One Biopharmaceuticals1$625

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$625 in reported general payments places this provider in the 55th percentile of 139 pediatric hematology-oncology providers in Pennsylvania.

See all pediatric hematology-oncology providers in Pennsylvania

Other pediatric hematology-oncology in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →